Phase II study of a full-dose THP-COP regimen for aggressive non-Hodgkin lymphoma in the elderly

Phase II study of a full-dose THP-COP regimen for aggressive non-Hodgkin lymphoma in the elderly - THP-1

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005636

Enrollment

Registered

2011-05-28

Start date

1999-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aggressive non Hodgkin lymphoma

Interventions

THP-COP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 70-79 years old 2) untreated intermediate-high grade NHL 3) clinical stage; I with bulky mass, II-IV 4) PS 0-1 5) adequate organ function as follows; a) neutrophil > 1.2 x 109/L b) platelet > 5.0 x 109/L c) AST and ALT < 5 times the upper limit of the normal d) total bilirubin < 2.0 mg/dL e) serum creatinin < 2.0 mg/dL g) PaO2 > 60 torr 6) written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients with any other malignancies 2)mental illness 3)a history of myocardial infarction or angina 4)central nervous system infiltration 5)uncontrollable diabetes 6)human immunodeficiency virus infection 7) hepatitis B virus surface antigen 8)hepatitis C virus antibody positivity

Design outcomes

Primary

Measure	Time frame
CR rate	—

Secondary

Measure	Time frame
failure-free survival overall survival toxicity	—

Countries

Japan

Contacts

Public ContactKen Ohmachi

Tokai University Division of hematology/oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026